Abstract
Resistance of tumor cells to chemotherapeutic agents and to radiation is one of the major obstacles in the treatment of human cancers. The exact mechanism by which cells develop resistance to chemotherapeutic and radiotherapeutic agents is not well understood. Accumulating evidences over the last decade suggests however that transcription factor nuclear factor-kappa B (NF-κ B) may play an important role in both chemoresistance and radioresistance. Three lines of evidence support this position. First, most chemotherapeutic agents and gamma radiation activate NF-κ B in vitro and in vivo. Second, induction of chemoresistance and radioresistance is mediated via genes regulated by NF-κ B. Third, inhibition of NF-κ B and NF-κ B-regulated gene products increases sensitivity of cancer cells to apoptotic action of chemotherapeutic agents and to radiation exposure. This review focuses on current knowledge of the regulation of resistance of tumors cells to chemotherapeutic agents and gamma radiation by NF-κ B and the therapeutic potential of targeting NF-κ B in cancer treatment.
Keywords: Chemoresistance, radioresistance, nuclear factor kappa B, chemosensitivity, radiosensitivity
Current Cancer Therapy Reviews
Title: Role of NF-κB and NF-κB-regulated Gene Products in Chemoresistance and Radioresistance
Volume: 2 Issue: 2
Author(s): Gautam Sethi and Bharat B. Aggarwal
Affiliation:
Keywords: Chemoresistance, radioresistance, nuclear factor kappa B, chemosensitivity, radiosensitivity
Abstract: Resistance of tumor cells to chemotherapeutic agents and to radiation is one of the major obstacles in the treatment of human cancers. The exact mechanism by which cells develop resistance to chemotherapeutic and radiotherapeutic agents is not well understood. Accumulating evidences over the last decade suggests however that transcription factor nuclear factor-kappa B (NF-κ B) may play an important role in both chemoresistance and radioresistance. Three lines of evidence support this position. First, most chemotherapeutic agents and gamma radiation activate NF-κ B in vitro and in vivo. Second, induction of chemoresistance and radioresistance is mediated via genes regulated by NF-κ B. Third, inhibition of NF-κ B and NF-κ B-regulated gene products increases sensitivity of cancer cells to apoptotic action of chemotherapeutic agents and to radiation exposure. This review focuses on current knowledge of the regulation of resistance of tumors cells to chemotherapeutic agents and gamma radiation by NF-κ B and the therapeutic potential of targeting NF-κ B in cancer treatment.
Export Options
About this article
Cite this article as:
Sethi Gautam and Aggarwal B. Bharat, Role of NF-κB and NF-κB-regulated Gene Products in Chemoresistance and Radioresistance, Current Cancer Therapy Reviews 2006; 2 (2) . https://dx.doi.org/10.2174/157339406776872834
DOI https://dx.doi.org/10.2174/157339406776872834 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of Fourth Generation ABC Inhibitors from Natural Products: A Novel Approach to Overcome Cancer Multidrug Resistance
Anti-Cancer Agents in Medicinal Chemistry Review of 5-HT4R Ligands: State of Art and Clinical Applications
Current Topics in Medicinal Chemistry An Overview on the Role of miR-451 in Lung Cancer: Diagnosis, Therapy, and Prognosis
MicroRNA Recent Progress in the Development of Natural ent-Kaurane Diterpenoids with Anti-tumor Activity
Mini-Reviews in Medicinal Chemistry Oncologic Imaging End-Points for the Assessment of Therapy Response
Recent Patents on Anti-Cancer Drug Discovery Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy
Recent Patents on Anti-Cancer Drug Discovery Obesity and Cancer: Biological Links and Treatment Implications
Current Cancer Drug Targets Inflammation, Microenvironment, and the Immune System in Cancer Progression
Current Pharmaceutical Design Current Developments in Anti-Fungal Agents
Current Medicinal Chemistry - Anti-Infective Agents Novel Concepts in the Development of Platinum Antitumor Drugs
Current Medicinal Chemistry - Anti-Cancer Agents Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions
Current Drug Targets Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Oral Anticoagulants for Venous Thromboembolism with Special Emphasis on Risk of Hemorrhagic Complications and Reversal Agents
Current Drug Therapy The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets Emerging Roles for Modulation of microRNA Signatures in Cancer Chemoprevention
Current Cancer Drug Targets Recent Progress of Src SH2 and SH3 Inhibitors as Anticancer Agents
Current Medicinal Chemistry Update on Evidence that Support a Role of Solar Ultraviolet-B Irradiance in Reducing Cancer Risk
Anti-Cancer Agents in Medicinal Chemistry Interactions of the Aryl Hydrocarbon Receptor with Inflammatory Mediators:Beyond CYP1A Regulation
Current Drug Metabolism Signaling Pathways Responsible for Cancer Cell Invasion as Targets for Cancer Therapy
Current Cancer Drug Targets A Review of Light Sources and Enhanced Targeting for Photodynamic Therapy
Current Medicinal Chemistry